|
|
Founders
Dr. Mike Goodnough.
Having graduated from the University of
Wisconsin-Madison in 1994 with a Ph.D. in Food Microbiology,
Dr. Goodnough
wrote his doctorate thesis on the medical use of botulinum toxin. Dr. Goodnough has
accumulated a great deal of toxin expertise over the last several years specializing in
the research and development of improving the toxin's characteristics and discovering
new applications. Mike has been a repeat speaker at the Interagency Botulinial Research
Committee Conference. He also is a co-author on three issued patents and three patent
applications. Prior to receiving his Ph.D., Mike obtained a M.S. in Food Microbiology and
a B.S. in Bacteriology and Genetics.
Carl Malizio has worked as a Senior
Research Specialist in the Department of Food Microbiology and Toxicology at the
University of Wisconsin-Madison since 1988. Concurrent with that position, Mr. Malizio
also functioned as Laboratory Supervisor for Interactive Biologics Associates from
1993-96. In that position, Carl was responsible for the manufacture of botulinum toxins
under cGMP's for medical use in humans. Product made in his laboratory passed
Phase I and II clinical trials, and although it is impossible to verify, it is likely that
Mr. Malizio has been involved with the largest number of successfully manufactured batches
of GMP grade botulinum toxin ever made. Carl received a B.S. with honors degree from the
University of Wisconsin-Madison Department of Bacteriology in 1988.
Terry Sivesind brings his
background in business development, marketing, and general management to the Company. His
business experience complements the scientific background of the three founders. Mr.
Sivesind has been involved with several successful biotechnology companies at the earliest
stages of their existence, including: Promega, PanVera and Mirus Corporations. He
will work with the Company to develop a company infrastructure, establish appropriate
business systems, and market toxin products to research customers.
|
|
